JD Health, the healthcare arm of China’s JD.com, has entered a deal to raise more than $830 million from Hillhouse Capital in a non-redeemable Series B preference share financing, JD.com said in its earnings release Monday.

JD.com said it will remain JD Health’s majority shareholder after the deal.

“By leveraging Hillhouse Capital’s industry expertise and resources, JD Health will further strengthen its pharmacy supply chain capabilities and explore additional healthcare services opportunities in the broader healthcare sector,” JD.com said.

The deal is expected to close during this year’s third quarter.

Hillhouse Capital CEO Lei Zhang didn’t immediately return a request for comment sent via LinkedIn outside of office hours.

JD Health had raised $1 billion in its Series A round led by JD.com, with participation from CPE, CICC and Baring Private Equity Asia, according to data from Crunchbase.

Hillhouse Capital’s previous healthcare investments include Joincare Pharmaceutical, biopharmaceutical development company BeiGene, late-stage biopharmaceutical company Everest Medicines and Genor Biopharma, according to Crunchbase.

Hillhouse Capital-backed Chinese biotechnology company Jacobio Pharmaceuticals, which focuses on cancer treatments, said it was planning a Hong Kong IPO possibly this year, according to a Bloomberg report earlier this month citing people familiar with the matter.

In June, JD Health launched its Traditional Chinese Medicine Consultation Center and its Intelligent Otorhinolaryngology Services Center, offering online consultations and disease management programs in China. Otorhinolaryngology covers diseases of the ear, nose and throat.

The new services broadened JD Health’s portfolio, which includes telemedicine for heart disease, mental health, diabetes, kidney disease, paediatrics, oncology and maternity.

In addition, JD Health Tuesday launched a new product called JD Family Doctor, allowing up to eight family members to share a package of medical services.

JD Retail CEO Lei Xu said in a separate company release Tuesday that the number of medical consultations via the platform is equivalent to the consultation volume of 10 3A, or the highest level, hospitals in China combined.

In a research note earlier this week, UOB KayHian said, citing management, that JD Health’s online medical consultations were up 400 per cent in the first half of this year, with net revenue up around 65 per cent on-year in the second quarter, even as its expense ratio was 10 per cent lower compared with offline pharmacies.

Related: JD.com Shuffles High-Level Executives to Lead New Health Care Unit